In the midst of the excitement surrounding CAR T therapies, much needs to be done to optimize CAR T cell efficacy. 2017 AACR Next Gen Grant Recipient Sidi Chen, PhD leveraged in vivo genome engineering methods and identified a new target to do just that.
Research Funding Impact
Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
The AACR-Conquer Cancer Foundation (CCF) of ASCO Young Investigator Award for Translational Cancer Research funds a physician-scientist during the transition from a fellowship program to a faculty appointment. 2020 Recipient Dr. Mathios speaks on the grant's impact on his research and career.
Because Cancer is Not an Island: 2020 AACR-The Mark Foundation for Cancer Research “Science of the Patient” SOP Grants
The 2020 AACR-The Mark Foundation for Cancer Research “Science of the Patient” SOP Grants Program seeks to stimulate novel research on the interplay between patient physiology and the tumor. The five grantees have been conducting breakthrough research -- studying cancer not as an isolated phenomenon but as a systemic disease.
Sarah Bohndiek, PhD, of the University of Cambridge. once thought she wanted to be an astrophysicist. She trained instead in radiation physics, and a grant from the AACR and Amgen helped her move into molecular imaging and early detection of cancer.
We are extremely proud of our past and present AACR grantees who have been selected to present their work via oral and poster presentations. We invite you to attend their talks and visit their posters to hear of the progress they have made with support, at least in part, from AACR and its funding partners.
A grant from the AACR in 2000 helped Karlyne Reilly, PhD, launch her career in cancer research. She is now head of the Rare Tumor Initiative at the National Cancer Institute and works to involve scientists, patients, family members, advocates, and healthcare providers in the search for treatments for rare cancers.
PanCAN-AACR Grantee Shows Potential Dual Anti-cancer and Anti-cachexia Benefits of Targeting Perp in Pancreatic Cancer
Cachexia is a muscle-wasting syndrome that is commonly found in pancreatic and other cancer patients. A group led by 2017 Pancreatic Cancer Action Network-AACR Career Development Award recipient Jason D. Doles, PhD, identified Perp as a novel tumor promoter and mediator of cancer-associated muscle wasting.
The AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowship Program is designed to encourage exceptional clinical research by bridging close collaboration between academia and industry. 2020 grant recipient Justin A. Chen, shares his perspectives on the impact of the grant.
2019 AACR-Amgen Fellow, Julia Frede, PhD, reported in Nature Cell Biology, how treatment can induce the expression of a distinct set of actionable immunotherapy targets in multiple myeloma, such as CXCR4, which can be exploited to keep treatment resistance at bay.